> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kura Oncology Expects Its Funding To Carry It Beyond 2028 Leukemia Trial Results
- URL: https://www.bullished.co/kura-oncology-expects-its-funding-to-carry-it-beyond-2028-leukemia-trial-results-88bcb0fe/
- Published: 2026-11-10T22:11:13.000Z
- Updated: 2026-11-10T22:11:13.000Z
- Description: KOMZIFTI revenue rose 53% from the second quarter, while Kura targets a 2027 start for an approval-focused salivary-gland cancer study.
- Author: Matteo Parrino
- Tags: Earnings, KURA, Industry: Healthcare

Kura Oncology, which sells the leukemia medicine KOMZIFTI, expects its $492.1 million in cash and investments, anticipated collaboration payments and conditional financing to [fund operations beyond](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526455416/kura-ex99%5F1.htm?ref=bullished.co) initial leukemia trial results anticipated in 2028\. The company reported the outlook Tuesday alongside its [quarterly SEC filing](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526455416/kura-20261110.htm?ref=bullished.co).

## KOMZIFTI Prescribing Gains Ground

Third-quarter KOMZIFTI revenue reached [$13.9 million](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526455416/kura-ex99%5F1.htm?ref=bullished.co), up 53% from the second quarter, against no product revenue a year earlier. Approximately 150 patients began treatment, up 30% from the previous quarter; prescriptions, including refills, exceeded 420, up 65%.

Kura said KOMZIFTI kept a majority of new patient starts among menin inhibitors in its approved leukemia market. The oral medicine treats adults whose acute myeloid leukemia has returned or resisted treatment, has a susceptible NPM1 mutation and lacks satisfactory alternatives. Kura books US sales and splits commercialization profits and losses equally with Kyowa Kirin, which manages commercialization outside the United States.

The quarterly net loss narrowed to $70.2 million, or $0.78 per share, from $74.1 million, or $0.85 per share, a year earlier. Non-cash stock compensation accounted for $8.2 million, versus $11.0 million. Research spending was $66.9 million against $67.9 million; selling and administrative spending fell to $30.2 million from $32.8 million.

## Funding Comes With Conditions And Costs

Kura held the [$492.1 million](https://www.globenewswire.com/news-release/2026/11/10/3400190/35186/en/kura-oncology-reports-third-quarter-2026-financial-results-and-corporate-update.html?ref=bullished.co) cash-and-investment balance at September 30, compared with $667.2 million at December 31, 2025\. Its funding outlook includes anticipated Kyowa Kirin milestone payments totaling $180 million and conditional Oberland Capital financing.

Oberland affiliates committed [up to $300 million](https://www.globenewswire.com/news-release/2026/11/10/3400190/35186/en/kura-oncology-reports-third-quarter-2026-financial-results-and-corporate-update.html?ref=bullished.co): up to $275 million in debt and $25 million in equity. Kura received $55 million at closing, comprising $50 million of debt before fees and a $5 million equity investment. Further funding depends on company options, milestones or mutual agreement.

The debt agreement runs for seven years. Loans carry interest of 6.95%–8.95%, with half the interest added to the loan balance during the first three years after each advance. A royalty of a few percent on US KOMZIFTI sales is capped at 20% of debt principal advanced.

Collaboration revenue declined to $8.9 million from $20.8 million a year earlier. Kura updated its 2026 forecast to $40 million–$45 million and maintained $90 million–$110 million for each of 2027 and 2028\. Those forecasts concern non-cash accounting recognition as work is performed, rather than when payments arrive.

## Darlifarnib's Route Toward Approval

Kura is enrolling newly diagnosed leukemia patients in its late-stage ziftomenib combination program, with initial results anticipated in 2028\. Eight abstracts are planned for the 2026 American Society of Hematology meeting, including two oral presentations on combinations with FLT3 inhibitors.

For darlifarnib, FDA agreement on the design of an approximately 40-patient salivary-gland cancer study provides “a potential path to our [second product approval](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526455416/kura-ex99%5F1.htm?ref=bullished.co),” said Troy Wilson, Kura Oncology's president and chief executive officer. Kura targets the first half of 2027 to begin the study, which will test the drug alone in patients with HRAS-mutant disease.

Kura also targets the first half of 2027 to finish enrollment in an early-stage kidney-cancer study combining darlifarnib with cabozantinib, with initial data expected in the second half. It plans an early-stage combination study with daraxonrasib in KRAS-mutated pancreatic cancer during the first half, aiming for preliminary data in the second half.

Outside cancer, Caspian Therapeutics completed a [$50 million financing](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526385881/d496500d8k.htm?ref=bullished.co) on September 8 to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases. Kura invested $4.3 million and owned approximately 49.2% immediately afterward, keeping that expansion in a separately financed company.

The next approval-focused step is the planned darlifarnib salivary-gland study in the first half of 2027; the larger leukemia program's initial results remain anticipated in 2028.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Kura Oncology, Inc. (KURA)](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526455416/kura-20261110.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit kura-ex99\_1.htm — Kura Oncology, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526455416/kura-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Kura Oncology Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/10/3400190/35186/en/kura-oncology-reports-third-quarter-2026-financial-results-and-corporate-update.html?ref=bullished.co) — globenewswire.com
- [8-K filed 2026-09-09 — Kura Oncology, Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526385881/d496500d8k.htm?ref=bullished.co) — SEC EDGAR